What is a stock summary page? Click here for an overview.
Business Description
IGM Biosciences Inc
NAICS : 325412
SIC : 2834
ISIN : US4495851085
Share Class Description:
IGMS: Ordinary SharesCompare
Compare
Traded in other countries / regions
IGMS.USA1K0.Germany Index Membership
Russell 2000Russell 3000 IPO Date
2019-09-18Description
IGM Biosciences Inc is a biotechnology company engaged in the development of IgM antibody therapeutics for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. Its IgM antibody technology platform is suited for developing T cell engagers, receptor cross-linking agonists, and targeted cytokines. Its product candidate, Aplitabart: An IgM antibody targeting Death Receptor 5 (DR5) proteins, for the treatment of colorectal cancer; Imvotamab: A bispecific for severe systemic lupus erythematosus (SLE) and one for severe rheumatoid arthritis (RA); and IGM-2644: A bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins, currently planned for evaluation in autoimmune disease.
Financial Strength
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 4.07 | |||||
| Equity-to-Asset | 0.18 | |||||
| Debt-to-Equity | 0.94 | |||||
| Debt-to-EBITDA | -0.23 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 3/9 | |||||
| Altman Z-Score | -6.85 | |||||
| Beneish M-Score | -3.19 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 11.8 | |||||
| 3-Year EPS without NRI Growth Rate | 13.1 | |||||
| 3-Year FCF Growth Rate | 14 | |||||
| 3-Year Book Growth Rate | -52.5 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | 36.41 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 59.17 |
Momentum Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 53.03 | |||||
| 9-Day RSI | 55.39 | |||||
| 14-Day RSI | 52.01 | |||||
| 3-1 Month Momentum % | -25.44 | |||||
| 6-1 Month Momentum % | -92.52 | |||||
| 12-1 Month Momentum % | -83.53 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 5.14 | |||||
| Quick Ratio | 5.14 | |||||
| Cash Ratio | 4.88 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -22.4 | |||||
| Shareholder Yield % | -2.13 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -7785.74 | |||||
| Net Margin % | -7308.51 | |||||
| FCF Margin % | -5929.38 | |||||
| ROE % | -159.45 | |||||
| ROA % | -57.38 | |||||
| ROIC % | -225.65 | |||||
| 3-Year ROIIC % | -175.76 | |||||
| ROC (Joel Greenblatt) % | -290.02 | |||||
| ROCE % | -69.22 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 29.33 | |||||
| PB Ratio | 1.63 | |||||
| Price-to-Tangible-Book | 1.63 | |||||
| EV-to-EBIT | 0.27 | |||||
| EV-to-EBITDA | 0.28 | |||||
| EV-to-Revenue | -20.94 | |||||
| EV-to-Forward-Revenue | 19.57 | |||||
| EV-to-FCF | 0.35 | |||||
| Price-to-GF-Value | 0.08 | |||||
| Earnings Yield (Greenblatt) % | 370.37 | |||||
| FCF Yield % | -201.32 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:IGMS
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
IGM Biosciences Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 2.679 | ||
| EPS (TTM) ($) | -3.24 | ||
| Beta | 0.88 | ||
| 3-Year Sharpe Ratio | -0.33 | ||
| 3-Year Sortino Ratio | -0.46 | ||
| Volatility % | 135.77 | ||
| 14-Day RSI | 52.01 | ||
| 14-Day ATR ($) | 0.126459 | ||
| 20-Day SMA ($) | 1.211 | ||
| 12-1 Month Momentum % | -83.53 | ||
| 52-Week Range ($) | 0.92 - 22.5 | ||
| Shares Outstanding (Mil) | 59.78 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
IGM Biosciences Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
IGM Biosciences Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| No Event Data | ||||
IGM Biosciences Inc Frequently Asked Questions
What is IGM Biosciences Inc(IGMS)'s stock price today?
The current price of IGMS is $1.32. The 52 week high of IGMS is $22.50 and 52 week low is $0.92.
When is next earnings date of IGM Biosciences Inc(IGMS)?
The next earnings date of IGM Biosciences Inc(IGMS) is 2025-05-08 Est..
Does IGM Biosciences Inc(IGMS) pay dividends? If so, how much?
IGM Biosciences Inc(IGMS) does not pay dividend.
Guru Commentaries on NAS:IGMS
No articles.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers